- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT01665911
An in Situ Study on the Impact of Fluoride Dose and Concentration in Milk on Its Anti-caries Efficacy
tiistai 3. helmikuuta 2015 päivittänyt: Frank Lippert
The study will be randomized, investigator-blind, observer-blind, laboratory analyst-blind and will utilize a 5-way cross-over study design with a primary objective to determine if a higher dose of fluoride in milk will provide a greater caries preventive effect.
Secondary objectives are to determine in a higher concentration of fluoride in milk will provide a greater caries preventive effect and if the caries preventive effect of fluoridated milk follows a dose-response pattern.
Tutkimuksen yleiskatsaus
Tila
Valmis
Ehdot
Yksityiskohtainen kuvaus
The evidence of milk fluoridation as a public health measure in caries prevention has been demonstrated in many clinical studies.
While these data are encouraging, the main focus now should be on the optimization of milk fluoride programs.
This protocol will concentrate on the parameters of fluoride dose and concentration utilizing an in situ model, the intra-oral caries test or model (ICT).
The ICT is an established model which features the use of gauze-covered specimens to facilitate plaque growth and to simulate a caries-prone/plaque stagnation area.
After subject has been consented and enrolled in the study per the inclusion/exclusion criteria, two to three days following a dental cleaning, two partially demineralized specimens will be placed in the buccal flange area of the subject's mandibular partial denture.
During each of the five, three-week test periods, subjects will drink their assigned milk test product once per day for either five (100 ml milk) or ten (200 ml milk) timed minutes, wearing their mandibular partial dentures 24 hours a day during the test period.
Fluoride free toothpaste will be used two to three days before and continuously during each treatment period.
After each three-week test period, the two partially demineralized specimens will be removed from the subject's partial denture and analyzed using the surface microhardness test.
Mineral content change (as percentage of surface microhardness recovery) in these artificially induced incipient enamel lesions will be the primary outcome variable.
Each subject (n = 28) will serve as his or her own control.
Opintotyyppi
Interventio
Ilmoittautuminen (Todellinen)
28
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskelupaikat
-
-
Indiana
-
Indianapolis, Indiana, Yhdysvallat, 46202
- Oral Health Research Institute, Indiana University School of Dentistry
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
18 vuotta - 80 vuotta (Aikuinen, Vanhempi Aikuinen)
Hyväksyy terveitä vapaaehtoisia
Joo
Sukupuolet, jotka voivat opiskella
Kaikki
Kuvaus
Inclusion Criteria:
- sign an informed consent, authorization for the release of health information for research and provide medical history information, including medications, prior to their participation;
- be between 18 and 80 years old and in general good health;
- willingness to use a reliable form of contraception or abstaining during the course of the study (females of child-bearing potential only)
- wear a removable mandibular partial denture with sufficient room in one posterior buccal flange area to accommodate two enamel specimens (required dimensions 12×7 mm);
- be willing and capable of wearing their removable mandibular partial dentures 24 hours a day for a total of five, three-week test periods;
- be in good dental health with no active caries or periodontal disease;
- agree to comply with all subjects' responsibilities as stated in the protocol (e.g. use of study products, attendance at appointments, etc.);
- have a salivary flow rate in the range of normal values (unstimulated whole saliva flow rate ≥ 0.2 ml/min; gum base stimulated whole saliva flow rate ≥ 0.8 ml/min).
- Be able to tolerate the taste and room temperature of the mixed milk product as demonstrated by drinking the milk at screening
Exclusion Criteria:
be pregnant, intending to become pregnant during the study period or breast feeding. A urine pregnancy test will be required at screening, the start of each treatment visit and the last study visit for all subjects of child-bearing potential to confirm the subject is not pregnant.
- have any medical condition that could be expected to interfere with the subject's safety during the study period;
- demonstrate an inability to comply with study procedures;
- have factors which could contraindicate their participation, such as any condition requiring the need for antibiotic premedication prior to a dental treatment, a condition requiring the need for long-term antibiotic use, blood thinning medications that prohibit the safe conduct of a dental cleaning* or previous use of the weight loss medications Fen Phen® or Redux®. (*Note: Subjects who are taking blood thinners in which written verification is obtained from their physician indicating their PT/INR levels (anti-coagulation blood levels) are at an acceptable level to avoid serious complications, such as bleeding during dental cleanings, may be accepted into the study at the discretion of the Investigator.)
- be currently taking or have ever taken a bisphosphonate drug (i.e. Fosamax®, Actonel®, Boniva®, Reclast®, or Zometa®) for treatment of osteoporosis.
- be lactose intolerant or have known allergy or intolerance to milk or milk products
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Jako: Satunnaistettu
- Inventiomalli: Crossover-tehtävä
- Naamiointi: Kaksinkertainen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Muut: Arm 1
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
|
Each subject will use this product during one of the five treatment periods in the crossover study design.
Muut nimet:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Muut nimet:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Muut nimet:
Each subject will use this product during one of the five treatment periods in the crossover study design
Muut nimet:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Muut nimet:
|
|
Muut: Arm 2
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
|
Each subject will use this product during one of the five treatment periods in the crossover study design.
Muut nimet:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Muut nimet:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Muut nimet:
Each subject will use this product during one of the five treatment periods in the crossover study design
Muut nimet:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Muut nimet:
|
|
Muut: Arm 3
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
|
Each subject will use this product during one of the five treatment periods in the crossover study design.
Muut nimet:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Muut nimet:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Muut nimet:
Each subject will use this product during one of the five treatment periods in the crossover study design
Muut nimet:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Muut nimet:
|
|
Muut: Arm 4
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
|
Each subject will use this product during one of the five treatment periods in the crossover study design.
Muut nimet:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Muut nimet:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Muut nimet:
Each subject will use this product during one of the five treatment periods in the crossover study design
Muut nimet:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Muut nimet:
|
|
Active Comparator: Arm 5
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
|
Each subject will use this product during one of the five treatment periods in the crossover study design.
Muut nimet:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Muut nimet:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Muut nimet:
Each subject will use this product during one of the five treatment periods in the crossover study design
Muut nimet:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
% Surface Microhardness (SMH) Recovery Score Per Each of Five Arms
Aikaikkuna: Three Weeks per each of five arms
|
|
Three Weeks per each of five arms
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
% Acid Resistance Score Per Each of Five Arms
Aikaikkuna: Three Weeks per each of five arms
|
% Acid Resistance is a measure of acid resistance of the remineralized caries lesion which is calculated as (D1-D2)/(D1-B)*100%, where B is the indentation length of sound enamel specimen at baseline, D1 is an indentation length after first in vitro demineralization, D2 is an indentation length after second in vitro demineralization.
|
Three Weeks per each of five arms
|
|
Enamel Fluoride Uptake Per Each of Five Arms
Aikaikkuna: Three Weeks per each of five arms
|
Enamel fluoride uptake is a measure of fluoridation of a caries lesion
|
Three Weeks per each of five arms
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Yhteistyökumppanit
Tutkijat
- Päätutkija: Domenick Zero, DDS, MS, Indiana University
Julkaisuja ja hyödyllisiä linkkejä
Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Keskiviikko 1. elokuuta 2012
Ensisijainen valmistuminen (Todellinen)
Maanantai 1. huhtikuuta 2013
Opintojen valmistuminen (Todellinen)
Lauantai 1. kesäkuuta 2013
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Tiistai 7. elokuuta 2012
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Maanantai 13. elokuuta 2012
Ensimmäinen Lähetetty (Arvio)
Torstai 16. elokuuta 2012
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Maanantai 23. helmikuuta 2015
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Tiistai 3. helmikuuta 2015
Viimeksi vahvistettu
Sunnuntai 1. helmikuuta 2015
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 12-I-086
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .